The following is a summary of “Efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis,” published in the November 2024 issue of Gastroenterology by Hu et al.    

Since 2015, CT-P13, a biosimilar of infliximab, has been approved for use in many countries, reducing the economic burden of patients and society with inflammatory bowel diseases (IBD).  

Researchers conducted a retrospective study to assess the efficacy of CT-P13 in treating IBD.  

They performed a random-effects meta-analysis (Stata MP 17) of 30 studies, evaluating the clinical response, remission, and mucosal healing in patients with IBD.  

The results showed that the pooled clinical remission rates for patients with Crohn’s disease (CD) and ulcerative colitis (UC) naïve to biologics at 8–14 weeks were 0.66 (95%CI, 0.58–0.75) and 0.48 (95% CI, 0.43–0.54), respectively, and at 100–104 weeks were 0.66 (95% CI, 0.49–0.84) and 0.71 (95% CI, 0.62–0.79), respectively. In patients who transitioned from the original agent, the clinical remission rates for CD and UC at 24–32 weeks were 0.84 (95% CI, 0.77–0.92) and 0.78 (95% CI, 0.63–0.93), respectively, and at 48–54 weeks were 0.72 (95% CI, 0.62–0.82) and 0.78 (95% CI, 0.71–0.86), respectively. Mucosal healing rates for UC were 0.56 (95% CI, 0.46–0.67) at 8–14 weeks and 0.64 (95% CI, 0.42–0.85) at 48–54 weeks showed no significant change in efficacy after switching treatments.  

They concluded that CT-P13 was an effective treatment for IBD both in the short and long term.  

Source: bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-024-03480-9